{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T13:20:15Z","timestamp":1783084815604,"version":"3.54.6"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,3]]},"DOI":"10.7759\/cureus.111987","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T12:34:44Z","timestamp":1783082084000},"source":"Crossref","is-referenced-by-count":0,"title":["Dolutegravir-Associated Dyslipidemia and Atherogenic Lipid Changes Among Treatment-Na\u00efve People Living With HIV: A 12-Month Prospective Cohort Study From Southern India"],"prefix":"10.7759","author":[{"given":"Savitha A","family":"Sebastian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cerin","family":"Devasia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumithra","family":"Selvam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jyothi","family":"Idiculla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens11020197","article-title":"Metabolic complications of chronic HIV infection: a narrative review","volume":"11","author":"Cummins NW","year":"2022","unstructured":"Cummins NW. Metabolic complications of chronic HIV infection: a narrative review. Pathogens. 2022, 11:197. 10.3390\/pathogens11020197","journal-title":"Pathogens"},{"key":"ref2","unstructured":"WHO. Interim Guidelines. Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV. (2018). Accessed: June 14, 2026: https:\/\/iris.who.int\/server\/api\/core\/bitstreams\/af680340-f5d0-404a-8e5d-932382f9d082\/content."},{"key":"ref3","unstructured":"National guidelines for HIV care and treatment 2021. (2021). Accessed. June 14, 2026: https:\/\/www.differentiatedservicedelivery.org\/wp-content\/uploads\/National_Guidelines_for_HIV_Care_and_Treatment_2021.pdf."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2020.100573","article-title":"Comparative efficacy, tolerability and safety of dolutegravir and efavirenz 400mg among antiretroviral therapies for first-line HIV treatment: a systematic literature review and network meta-analysis","volume":"28","author":"Kanters S","year":"2020","unstructured":"Kanters S, Vitoria M, Zoratti M, et al.. Comparative efficacy, tolerability and safety of dolutegravir and efavirenz 400mg among antiretroviral therapies for first-line HIV treatment: a systematic literature review and network meta-analysis. EClinicalMedicine. 2020, 28:100573. 10.1016\/j.eclinm.2020.100573","journal-title":"EClinicalMedicine"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215541","article-title":"Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection","volume":"369","author":"Walmsley SL","year":"2013","unstructured":"Walmsley SL, Antela A, Clumeck N, et al.. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N Engl J Med. 2013, 369:1807-18. 10.1056\/NEJMoa1215541","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz407","article-title":"Greater weight gain in treatment-naive persons starting dolutegravir-based antiretroviral therapy","volume":"70","author":"Bourgi K","year":"2020","unstructured":"Bourgi K, Rebeiro PF, Turner M, et al.. Greater weight gain in treatment-naive persons starting dolutegravir-based antiretroviral therapy. Clin Infect Dis. 2020, 70:1267-74. 10.1093\/cid\/ciz407","journal-title":"Clin Infect Dis"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(20)30241-1","article-title":"Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial","volume":"7","author":"Venter WD","year":"2020","unstructured":"Venter WD, Sokhela S, Simmons B, et al.. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial. Lancet HIV. 2020, 7:e666-76. 10.1016\/S2352-3018(20)30241-1","journal-title":"Lancet HIV"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2024-097340","article-title":"Metabolic syndrome among a Ghanaian cohort living with HIV initiated on dolutegravir in a real-world setting: a prospective study","volume":"15","author":"Torpey K","year":"2025","unstructured":"Torpey K, Ganu V, Kenu E, et al.. Metabolic syndrome among a Ghanaian cohort living with HIV initiated on dolutegravir in a real-world setting: a prospective study. BMJ Open. 2025, 15:e097340. 10.1136\/bmjopen-2024-097340","journal-title":"BMJ Open"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa259","article-title":"The integrase inhibitors dolutegravir and raltegravir exert proadipogenic and profibrotic effects and induce insulin resistance in human\/simian adipose tissue and human adipocytes","volume":"71","author":"Gorwood J","year":"2020","unstructured":"Gorwood J, Bourgeois C, Pourcher V, et al.. The integrase inhibitors dolutegravir and raltegravir exert proadipogenic and profibrotic effects and induce insulin resistance in human\/simian adipose tissue and human adipocytes. Clin Infect Dis. 2020, 71:e549-60. 10.1093\/cid\/ciaa259","journal-title":"Clin Infect Dis"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10163456","article-title":"Do all integrase strand transfer inhibitors have the same lipid profile? Review of randomised controlled trials in na\u00efve and switch scenarios in HIV-infected patients","volume":"10","author":"Saumoy M","year":"2021","unstructured":"Saumoy M, Sanchez-Quesada JL, Ordo\u00f1ez-Llanos J, Podzamczer D. Do all integrase strand transfer inhibitors have the same lipid profile? Review of randomised controlled trials in na\u00efve and switch scenarios in HIV-infected patients. J Clin Med. 2021, 10:3456. 10.3390\/jcm10163456","journal-title":"J Clin Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000002811","article-title":"Incidence of dyslipidemia in people with HIV who are treated with integrase inhibitors versus other antiretroviral agents","volume":"35","year":"2021","unstructured":"Incidence of dyslipidemia in people with HIV who are treated with integrase inhibitors versus other antiretroviral agents. AIDS. 2021, 35.869-82. 10.1097\/QAD.0000000000002811","journal-title":"AIDS"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0247004","article-title":"Prevalence of low high-density lipoprotein among young adults receiving antiretroviral therapy in Zambia: an opportunity to consider non-communicable diseases in resource-limited settings","volume":"16","author":"Hamooya BM","year":"2021","unstructured":"Hamooya BM, Musonda P, Mutale W, et al.. Prevalence of low high-density lipoprotein among young adults receiving antiretroviral therapy in Zambia: an opportunity to consider non-communicable diseases in resource-limited settings. PLoS One. 2021, 16:e0247004. 10.1371\/journal.pone.0247004","journal-title":"PLoS One"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2304146","article-title":"Pitavastatin to prevent cardiovascular disease in HIV infection","volume":"389","author":"Grinspoon SK","year":"2023","unstructured":"Grinspoon SK, Fitch KV, Zanni MV, et al.. Pitavastatin to prevent cardiovascular disease in HIV infection. N Engl J Med. 2023, 389:687-99. 10.1056\/NEJMoa2304146","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2025.11.016","article-title":"2026 ACC\/AHA\/AACVPR\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Dyslipidemia: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"87","author":"Blumenthal RS","year":"2026","unstructured":"Blumenthal RS, Morris PB, Gaudino M, et al.. 2026 ACC\/AHA\/AACVPR\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Dyslipidemia: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2026, 87:2624-757. 10.1016\/j.jacc.2025.11.016","journal-title":"J Am Coll Cardiol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.2147\/POR.S361907","article-title":"A phase IV study on safety, tolerability and efficacy of dolutegravir, lamivudine, and tenofovir disoproxil fumarate in treatment na\u00efve adult Indian patients living with HIV-1","volume":"13","author":"Dravid A","year":"2022","unstructured":"Dravid A, Morkar D, Prasad D, et al.. A phase IV study on safety, tolerability and efficacy of dolutegravir, lamivudine, and tenofovir disoproxil fumarate in treatment na\u00efve adult Indian patients living with HIV-1. Pragmat Obs Res. 2022, 13:75-84. 10.2147\/POR.S361907","journal-title":"Pragmat Obs Res"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.62522","article-title":"Clinical profile and adverse effects of dolutegravir treatment in HIV-positive patients: a prospective observational study","volume":"16","author":"Joshi K","year":"2024","unstructured":"Joshi K, Shinde S, Karatela S, Mulkalwar A. Clinical profile and adverse effects of dolutegravir treatment in HIV-positive patients: a prospective observational study. Cureus. 2024, 16:e62522. 10.7759\/cureus.62522","journal-title":"Cureus"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.56424","article-title":"Adverse drug reactions and prescription patterns of antiretroviral drugs: a longitudinal observational study from a tertiary care hospital in Western India","volume":"16","author":"Sekar VD","year":"2024","unstructured":"Sekar VD, Joshi K, Bhide S, et al.. Adverse drug reactions and prescription patterns of antiretroviral drugs: a longitudinal observational study from a tertiary care hospital in Western India. Cureus. 2024, 16:e56424. 10.7759\/cureus.56424","journal-title":"Cureus"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.19.2486","article-title":"Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)","volume":"285","year":"2001","unstructured":"Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001, 285.2486-97. 10.1001\/jama.285.19.2486","journal-title":"JAMA"},{"key":"ref19","unstructured":"The Asia-Pacific perspective. redefining obesity and its treatment. (2000). Accessed: June 16, 2026: https:\/\/iris.who.int\/server\/api\/core\/bitstreams\/53228dc6-9520-421b-b5a2-f826967090cb\/content."},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0250328","article-title":"Prevalence of dyslipidaemia among HIV-infected patients receiving combination antiretroviral therapy in North Shewa, Ethiopia","volume":"16","author":"Fiseha T","year":"2021","unstructured":"Fiseha T, Alemu W, Dereje H, Tamir Z, Gebreweld A. Prevalence of dyslipidaemia among HIV-infected patients receiving combination antiretroviral therapy in North Shewa, Ethiopia. PLoS One. 2021, 16:e0250328. 10.1371\/journal.pone.0250328","journal-title":"PLoS One"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3390\/nu5072708","article-title":"Obesity and dyslipidemia in South Asians","volume":"5","author":"Misra A","year":"2013","unstructured":"Misra A, Shrivastava U. Obesity and dyslipidemia in South Asians. Nutrients. 2013, 5:2708-33. 10.3390\/nu5072708","journal-title":"Nutrients"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-023-08892-8","article-title":"Dyslipidemia among adult people living with HIV on dolutegravir - based antiretroviral therapy at a private tertiary hospital in Kampala, Uganda: burden and determinants","volume":"24","author":"Kigongo VJ","year":"2024","unstructured":"Kigongo VJ, Nankabirwa JI, Kitutu FE, et al.. Dyslipidemia among adult people living with HIV on dolutegravir - based antiretroviral therapy at a private tertiary hospital in Kampala, Uganda: burden and determinants. BMC Infect Dis. 2024, 24:53. 10.1186\/s12879-023-08892-8","journal-title":"BMC Infect Dis"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ296","article-title":"The lipid-lowering effect of tenofovir\/emtricitabine: a randomized, crossover, double-blind, placebo-controlled trial","volume":"61","author":"Santos JR","year":"2015","unstructured":"Santos JR, Saumoy M, Curran A, et al.. The lipid-lowering effect of tenofovir\/emtricitabine: a randomized, crossover, double-blind, placebo-controlled trial. Clin Infect Dis. 2015, 61:403-8. 10.1093\/cid\/civ296","journal-title":"Clin Infect Dis"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12113644","article-title":"Weight and metabolic outcomes in na\u00efve HIV patients treated with integrase inhibitor-based antiretroviral therapy: a systematic review and meta-analysis","volume":"12","author":"Valenzuela-Rodriguez G","year":"2023","unstructured":"Valenzuela-Rodriguez G, Diaz-Arocutipa C, Collins JA, Hernandez AV. Weight and metabolic outcomes in na\u00efve HIV patients treated with integrase inhibitor-based antiretroviral therapy: a systematic review and meta-analysis. J Clin Med. 2023, 12:3644. 10.3390\/jcm12113644","journal-title":"J Clin Med"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.7326\/M20-4853","article-title":"Weight and metabolic changes after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in people living with HIV : a cohort study","volume":"174","author":"Surial B","year":"2021","unstructured":"Surial B, Mugglin C, Calmy A, et al.. Weight and metabolic changes after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in people living with HIV : a cohort study. Ann Intern Med. 2021, 174:758-67. 10.7326\/M20-4853","journal-title":"Ann Intern Med"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.19607","article-title":"Advancing age and risk from the elevated atherogenic index: triglyceride (TG) to high-density cholesterol (HDL-C) ratio","volume":"73","author":"Kumar M","year":"2025","unstructured":"Kumar M, Zhao S, Robinson P, et al.. Advancing age and risk from the elevated atherogenic index: triglyceride (TG) to high-density cholesterol (HDL-C) ratio. J Am Geriatr Soc. 2025, 73:2738-46. 10.1111\/jgs.19607","journal-title":"J Am Geriatr Soc"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12071493","article-title":"The triglyceride\/HDL ratio as a surrogate biomarker for insulin resistance","volume":"12","author":"Baneu P","year":"2024","unstructured":"Baneu P, V\u0103c\u0103rescu C, Dr\u0103gan SR, et al.. The triglyceride\/HDL ratio as a surrogate biomarker for insulin resistance. Biomedicines. 2024, 12:1493. 10.3390\/biomedicines12071493","journal-title":"Biomedicines"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-7141.2008.00011.x","article-title":"Association of total cholesterol\/ high-density lipoprotein cholesterol ratio with proximal coronary atherosclerosis detected by multislice computed tomography","volume":"12","author":"Nair D","year":"2009","unstructured":"Nair D, Carrigan TP, Curtin RJ, et al.. Association of total cholesterol\/ high-density lipoprotein cholesterol ratio with proximal coronary atherosclerosis detected by multislice computed tomography. Prev Cardiol. 2009, 12:19-26. 10.1111\/j.1751-7141.2008.00011.x","journal-title":"Prev Cardiol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1177\/2047487319862401","article-title":"Total cholesterol\/HDL-cholesterol ratio discordance with LDL-cholesterol and non-HDL-cholesterol and incidence of atherosclerotic cardiovascular disease in primary prevention: the ARIC study","volume":"27","author":"Quispe R","year":"2020","unstructured":"Quispe R, Elshazly MB, Zhao D, et al.. Total cholesterol\/HDL-cholesterol ratio discordance with LDL-cholesterol and non-HDL-cholesterol and incidence of atherosclerotic cardiovascular disease in primary prevention: the ARIC study. Eur J Prev Cardiol. 2020, 27:1597-605. 10.1177\/2047487319862401","journal-title":"Eur J Prev Cardiol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2012.04440.x","article-title":"A phase 1 study to evaluate the effect of dolutegravir on renal function via measurement of iohexol and para-aminohippurate clearance in healthy subjects","volume":"75","author":"Koteff J","year":"2013","unstructured":"Koteff J, Borland J, Chen S, et al.. A phase 1 study to evaluate the effect of dolutegravir on renal function via measurement of iohexol and para-aminohippurate clearance in healthy subjects. Br J Clin Pharmacol. 2013, 75:990-6. 10.1111\/j.1365-2125.2012.04440.x","journal-title":"Br J Clin Pharmacol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/507996-dolutegravir-associated-dyslipidemia-and-atherogenic-lipid-changes-among-treatment-nave-people-living-with-hiv-a-12-month-prospective-cohort-study-from-southern-india","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T12:34:58Z","timestamp":1783082098000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/507996-dolutegravir-associated-dyslipidemia-and-atherogenic-lipid-changes-among-treatment-nave-people-living-with-hiv-a-12-month-prospective-cohort-study-from-southern-india"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,3]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.111987","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,3]]}}}